Team ID	PNT2022TMID10840
Student Name	Mr. ASHWIN RUPAK S A B
Student Roll Number	811519104013

TEAM LEADER : ASHWIN RUPAK S A B

TEAM MEMBER 1: HARISSH S

TEAM MEMBER 2: JANARTHANAN J

TEAM MEMBER 3: KISHORE KUMAR N

Project Output




IBM Cloud
Home - Plasma Life Saver
127.0.0.1:5000/index?user=%7B%27username%27%3A+%27%27%7D
Plasma Life Saver
Dashboard
Search
Notifications
Hi, Ash
Logout
Search by:
Blood Group
Search
Search
Registered donors:


IBM Cloud
Welcome to Plasma Life Saver
127.0.0.1:5000/notifyusers
Plasma Life Saver
Dashboard
Search
Notifications
Hi, Ash
Logout
from ashmail@gmail.com
Jana sent you a plasma request his address is
Need Plasma
Rejected
from ashmail@gmail.com
ash sent you a plasma request his address is
Need Blood
Accepted
from ashmail@gmail.com
Hey Jana sent you a plasma request his address is
I need some plasma for my friend
Rejected


IBM Cloud
Welcome to Plasma Life Saver
127.0.0.1:5000/login
Plasma Life Saver
Home
Login
Register
News
Trends
Email address
jana@gmail.com
We'll never share your email with anyone else.
Password
User Type
Donor
Login


IBM Cloud
Welcome to Plasma Life Saver
127.0.0.1:5000/myprofile/jana%40gmail.com
Plasma Life Saver
Home
My Profile
Notifications
Hi, Janarthanan
Logout
Donor Information
Name
Janarthanan
Address
Jana Address
City
Jana City
Pin
Ilasdad
Blood group
B+
Email address
jana@gmail.com
Available


IBM Cloud
Welcome to Plasma Life Saver
127.0.0.1:5000/notifications
Plasma Life Saver
Home
My Profile
Notifications
Hi, Janarthanan
Logout
from ashmail@gmail.com
Jana sent you a plasma request his address is
Need Plasma
Rejected
from ashmail@gmail.com
ash sent you a plasma request his address is
Need Blood
Accepted
from ashmail@gmail.com
Hey Jana sent you a plasma request his address is
I need some plasma for my friend
Rejected


IBM Cloud
Welcome to Plasma Life Saver
127.0.0.1:5000/news
Plasma Life Saver
Home
Login
Register
News
Trends
300ml*
HOW IS LAB-GROWN BLOOD MADE?
RESEARCH
To create lab-grown blood, the researchers in this trial separate stem cells from the RBCs present within the blood provided by NHSBT donors. More specifically, magnetic beads were used to detect flexible stem cells within the samples that have the potential to eventually be transformed into RBCs.
THE FIRST TRANSFUSIONS
As of November 7, 2022, two patients in the RESTORE trial have been transfused with very small amounts between five and ten milliliters (ml) of the lab-grown RBCs. Both individuals appear to tolerate the transfusions well and have not reported any notable side effects.
ABOUT THE RESTORE TRIAL
The RESTORE trial is a single-center, randomized, controlled, phase I cross-over trial that is a joint effort between the National Health Service (NHS) Blood and Transplant (NHSBT) and the University of Bristol. The aim of this trial is to determine whether blood cells manufactured from donor stem cells perform better than red blood cells (RBCs) obtained from the same donor in recipients.


IBM Cloud
Welcome to Plasma Life Saver
127.0.0.1:5000/trend
Plasma Life Saver
Home
Login
Register
News
Trends
ESTABLISHING THE OPTIMAL TREATMENT FOR COVID-19 PATIENTS REMAINS CHALLENGING. SPECIFICALLY, IMMUNOCOMPROMISED AND PRE-DISEASED PATIENTS ARE AT HIGH RISK FOR SEVERE DISEASE COURSE AND FACE LIMITED THERAPEUTIC OPTIONS.
CONVALESCENT PLASMA
Convalescent plasma (CP) has been considered as therapeutic approach, but reliable data are lacking, especially for high-risk patients. We performed a retrospective analysis of 55 hospitalized COVID-19 patients from University Hospital Duesseldorf (UKD) at high risk for disease progression
USAGE
Convalescent plasma has been used during pandemics caused by influenza (1918)9, Severe Acute Respiratory Syndrome associated Corona-Virus SARS-CoV (2003) and influenza H1N1 (2009) and is reported to have resulted in lower mortality.
MORTALITY RATE
The aggregate mortality rate was lower in the transfused group than in the control groups. A major determinant was the timing of CP administration: early transfusion (within 3 days of hospital admission) with high antibody titers resulted in lower mortality.


IBM Cloud
Welcome to Plasma Life Saver
127.0.0.1:5000/dashboard
Plasma Life Saver
Dashboard
Search
Notifications
Hi, Ash
Logout
300ml*
0:00 / 1:19


IBM Cloud
Home - Plasma Life Saver
127.0.0.1:5000/index?user=%7B%27username%27%3A+%27%27%7D
Plasma Life Saver
Dashboard
Search
Notifications
Hi, Ash
Logout
Search by:
Blood Group
Search
Search
Registered donors: